Survey
Quarterly Survey: Frown Line Treatments with a focus on Revance's Daxxify July 2023
Ticker(s): RVNC, ABBV, IPN, EOLSSurvey results include 20 Dermatologists.
What is the number of patients you treat with frown line injections on average each month?
How would you best describe your practice?
What is the percentage breakdown of frown line
injection brands you currently use? Please specify between 0-100 for each
(sum to 100%)
- Daxxify:
- Botox:
- Dysport:
- Jeuveau:
- Xeomin:
- Other:
Which injection do you prefer to use for the treatment? Select one.
- Daxxify
- Botox
- Jeuveau
- Xeomin
- Dysport
Please elaborate on your brand preference.
How many of your patients currently use Daxxify?
How many patients do you expect to start Daxxify in the next 30 days?
Do you expect your usage of Daxxify to increase moving forward?
Why or why not? Please be specific.
How would you rate Daxxify on the following (where 1 is low and 5 is high)?
- Safety
- Efficacy
- Payor Access
What features being added to future generations of injection treatments would have you consider switching brands or significantly shifting share?
What changes, if any, have you noticed with payor reimbursement and insurance for frown line injections?
Are You Interested In These Questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
